CELEX: 62017TA0036
Language: en
Date: 2017-10-05 00:00:00
Title: Case T-36/17: Judgment of the General Court of 5 October 2017 — Forest Pharma v EUIPO — Ipsen Pharma (COLINEB) (EU trade mark — Opposition proceedings — Application for EU word mark COLINEB — Earlier national figurative mark Colina — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) — Extent of the examination to be carried out by the Board of Appeal — Article 76(1) of Regulation No 207/2009 (now Article 95(1) of Regulation (EU) 2017/1001))

20.11.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 392/25
            
         Judgment of the General Court of 5 October 2017 — Forest Pharma v EUIPO — Ipsen Pharma (COLINEB)
   (Case T-36/17) (1)
   
   ((EU trade mark - Opposition proceedings - Application for EU word mark COLINEB - Earlier national figurative mark Colina - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Extent of the examination to be carried out by the Board of Appeal - Article 76(1) of Regulation No 207/2009 (now Article 95(1) of Regulation (EU) 2017/1001)))
   (2017/C 392/31)
   Language of the case: English
   
      Parties
   
   
      Applicant: Forest Pharma BV (Amsterdam, Netherlands) (represented by: T. Holman, Solicitor)
   
      Defendant: European Union Intellectual Property Office (represented by: P. Sipos, acting as Agent)
   
      Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Ipsen Pharma SAS (Boulogne-Billancourt, France) (represented by: E. Baud, lawyer)
   
      Re:
   
   Action brought against the decision of the Fifth Board of Appeal of EUIPO of 13 October 2016 (Case R 500/2016-5), relating to opposition proceedings between Ipsen Pharma and Forest Pharma.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the action;
            
         
               2.
            
            
               Orders Forest Pharma BV to bear its own costs and to pay the costs incurred by the European Union Intellectual Property Office (EUIPO);
            
         
               3.
            
            
               Orders Ipsen Pharma SAS to bear its own costs.
            
         
      (1)  OJ C 70, 6.3.2017.